Form 4: Rigel CEO's Routine Share Withholding for Taxes

Rigel Pharmaceuticals CEO Raul R. Rodriguez reported a disposition of 7,607 common shares for tax obligations related to equity compensation.

Summary

• Raul R. Rodriguez, CEO and President of Rigel Pharmaceuticals Inc. (RIGL), reported a transaction on February 10, 2026.
• The transaction involved the disposition of 7,607 shares of common stock.
• These shares were disposed of at a price of $34.62 per share.
• The transaction code 'F' indicates that these shares were withheld to cover tax liabilities incident to the vesting or exercise of equity compensation.
• Following this transaction, Mr. Rodriguez directly beneficially owns 228,102 shares of Rigel Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a standard, non-discretionary transaction related to executive compensation and does not indicate a change in company fundamentals or management's confidence.

Positives

• The transaction is a routine, non-discretionary event related to equity compensation, indicating standard executive compensation practices are in place.

Negatives

• A reduction in direct beneficial ownership, though for tax purposes, slightly decreases the CEO's direct stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as share withholdings for tax purposes, are common across the biotechnology and pharmaceutical industries as part of executive compensation packages. These events typically do not reflect a change in management's outlook or strategic direction.

Comparison to Industry Standards

• This type of transaction (shares withheld for tax liability) is a standard practice for equity compensation plans across publicly traded companies, including those in the pharmaceutical sector. It aligns with common executive compensation structures where stock awards vest, and a portion is automatically sold or withheld to cover income tax obligations.

Stakeholder Impact

• Shareholders: The transaction is a routine administrative event and is unlikely to have a material impact on shareholder value or perception.
• Management: The CEO's overall beneficial ownership remains substantial, aligning his interests with long-term company performance, despite the minor reduction for tax purposes.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by the CEO for tax purposes related to equity compensation. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not present a catalyst for buying or selling.

Keywords

Rigel Pharmaceuticals, RIGL, Raul R. Rodriguez, SEC Form 4, Insider Transaction, Share Withholding, Tax Obligation, Equity Compensation, CEO